Published in World J Exp Med on February 20, 2016
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J Gastroenterol (2016) 0.78
Focal loss of long non-coding RNA-PRAL, as determinant of cell function and phenotype of hepatocellular carcinoma. Ann Transl Med (2016) 0.78
CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma. J Exp Clin Cancer Res (2017) 0.77
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLoS One (2017) 0.75
The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer. J Histochem Cytochem (2016) 0.75
HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med (2016) 0.75
Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma. Cell Death Dis (2017) 0.75
Burden of Cancers Attributable to Infectious Agents in Nigeria: 2012-2014. Front Oncol (2016) 0.75
Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.75
Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer. Int J Mol Sci (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A (2009) 2.07
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.76
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med (2000) 1.71
Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg (2006) 1.71
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene (2003) 1.63
Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One (2013) 1.63
Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology (2014) 1.54
Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg (2001) 1.52
Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis (2015) 1.51
Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology (2015) 1.49
Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med (1996) 1.44
Molecular biology of liver cancer stem cells. Liver Cancer (2014) 1.41
Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology (2015) 1.39
Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis (2005) 1.29
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther (2014) 1.23
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol (2013) 1.23
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol (2010) 1.22
Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg (2001) 1.15
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol (2007) 1.14
Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med (2007) 1.14
Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.11
DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev (2013) 1.09
Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology (2011) 1.08
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl (2012) 1.06
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology (2015) 1.04
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer (2014) 1.04
Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis (2013) 1.04
Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer (2014) 1.04
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev (2014) 1.01
Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 1.00
DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology (2015) 1.00
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol (2011) 1.00
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology (1997) 1.00
Cancer risk: role of environment—response. Science (2015) 0.99
Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol (2015) 0.98
Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology (2012) 0.98
Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther (2013) 0.97
Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review. Anticancer Res (2014) 0.97
Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res (2015) 0.96
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol (2015) 0.95
Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol (2013) 0.94
Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res (2006) 0.93
Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes. Radiology (2015) 0.93
Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol (2015) 0.92
Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol (2003) 0.91
Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol (2013) 0.91
Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res (2015) 0.90
Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol (2016) 0.89
Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol (2015) 0.89
Liver Transplantation: East versus West. J Clin Exp Hepatol (2013) 0.89
Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients. J Cancer Res Clin Oncol (2013) 0.89
Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol (2015) 0.88
Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol (2015) 0.88
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 0.88
Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study. Int J Cancer (2013) 0.88
Surgical management of hepatocellular carcinoma. World J Hepatol (2015) 0.87
Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology (2015) 0.87
Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer (2015) 0.87
Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer. Onco Targets Ther (2015) 0.86
Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol (2015) 0.85
Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology (2015) 0.84
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol (2014) 0.84
Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study. J Gastrointest Surg (2011) 0.84
Does living donation have advantages over deceased donation in liver transplantation? J Gastroenterol Hepatol (2010) 0.84
Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol (2015) 0.84
Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J Med Virol (2002) 0.84
Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol (2015) 0.83
Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol (2010) 0.83
Current management of patients with hepatocellular carcinoma. World J Hepatol (2015) 0.82
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer (2015) 0.82
Fruit and vegetable consumption in relation to hepatocellular carcinoma in a multi-centre, European cohort study. Br J Cancer (2015) 0.82